Here are some pictures of the first edition 

Brenus Pharma has developped innovative technology of Stimulated Tumor Cells to stimulate host immune system to induce response following education to recognize tumor associated antigens and tumor specific antigens expressed during treatment with chemotherapy or radiotherapy. 

Evora Biosciences develops exosome-based treatments, a cell-free alternative to cell therapies and the next building block for regenerative medecine.  

IMESCIA is a preclinical-stage company developing a new formulation for anticancer highly potent APIs to unlock their full potential.  

To adress the unmet need to dispose of relevant tools to value the efficacy of treatments for red blood cell disorders, INNOVHEM has developed two important and unique innovations :a simple and accurate method to quantify fetal hemoglobin in each red blood cell and a specific new method to measure intravascular hemolysis. Together with several generic biological assays, INNOVHEM offers a comprehensive and innovative platform that supports the development of new treatments for red blod cell pathologies, from preclinical to phase IV evaluation.  

MAbSilico is a deeptech company from French academic research labs. Founded in 2017, MAbSilico is a software editor with the vision to accelerate the development of therapeutic antibody focusing on the early stage development to provide leads in a few years today to a few weeks.

SYNSIGHT Pharmaceuticals aims to make Drug Discovery faster, cheaper and smarter. Early-Stage Drug Discovery includes many Design-and-Test cycles. A large Pharma company may go through 25 cycles or more in a single year! This is where Synsight comes in: we help our clients and partners to make focused decisions on which molecules to make; how and why certain molecules exert a biological activity (or fail to); how to enhance the activity or selectivity of lead molecules, or make them more drug-like; and even how to find new indications for known drugs.